Skip to Content

'
David C. Rice, M.B., B.Ch., B.A.O.; F.R.C.S.I.

Present Title & Affiliation

Primary Appointment

Professor, Department of Thoracic and Cardiovascular Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

 Dr. Rice was born and raised in Dublin, Ireland. He received his medical degree (M.B., B.Ch.) at the School of Medicine, Trinity College, the University of Dublin in 1991 and then completed his internship at St James Hospital, Dublin, Ireland in 1992. He left Ireland in 1992 to obtain his general surgery residency training at the Mayo Clinic, Rochester, MN in 1999. During this time Dr. Rice took 18 months to complete a research fellowship in tumor immunology, examining ways of stimulating T-cells of the immune system to better fight cancer. Dr. Rice went on to continue training in Thoracic and Cardiovascular Surgery at the Baylor College of Medicine and at The UT M. D. Anderson Cancer Center from 1999 – 2001. Dr. Rice joined the faculty of the Department of Thoracic and Cardiovascular Surgery at The University of Texas M. D. Anderson Cancer Center in 2001 where he is currently a Professor in Surgery.

Research Interests

Dr. Rice’s research efforts have centered mainly on clinical research.  He is the surgical principal investigator (PI) on the Vanguard study, which prospectively examines the use of novel targeted biological agents to prevent cancer recurrence in patients who have undergone surgery for lung cancer. Dr. Rice is also the surgical PI on a prospective randomized trial to evaluate the hemostatic effects of aprotinin during extrapleural pneumonectomy.   He is the institutional PI for an American College of Surgeons Oncology Group clinical protocol (Z0040) and the institutional surgical PI on two other multi-center trials. One of these investigates the significance in circulating tumor cells in patients undergoing lung cancer surgery, and the other is a prospective trial of neoadjuvant chemotherapy, extrapleural pneumonectomy, and adjuvant radiation therapy in patients with malignant pleural mesothelioma.

Clinical Interests

 Since joining MD Anderson, Dr. Rice has striven to provide the best and most modern surgical care possible to patients with thoracic malignancies. His clinical interests have followed two very divergent paths. First, to continue to be a leader in the field of thoracic surgery by pushing the envelope and practicing new and more innovative ways of doing surgery that impart less surgical trauma and pain for the patient and yet offer the same oncologic benefit as traditional procedures. Dr. Rice and his colleagues have been active in greatly expanding the role of video assisted thoracoscopic (VATS) surgery in thoracic malignancies. Dr. Rice was the first surgeon to perform a minimally invasive esophagectomy at this institution. This is a technically demanding and highly complex procedure that is routinely performed at only a handful of other centers, and offers patients the potential for easier recovery with less pain and fewer pulmonary side effects than does a traditional ‘open’ surgery. Similarly, Dr. Rice and his colleagues have greatly expanded the use of minimally invasive lobectomy and now offer this procedure routinely for patients with small localized lung cancers.

Dr. Rice participated as a founder in the development of the MINTOS (Minimally Invasive and New Technologies in Oncologic Surgery) working group and has fostered the use of endobronchial ultrasound (EBUS) guided mediastinal nodal biopsies in thoracic malignancies.   With this advanced bronchoscopic method it is possible to accurately sample mediastinal lymph nodes using a video bronchoscope that has an ultrasound probe at its tip. The presence of mediastinal nodal metastases in patients with lung cancer dramatically alters management and prognosis, and prior to the development of EBUS it was possible to accurately biopsy these nodes only with mediastinoscopy, an invasive and occasionally morbid procedure. EBUS is now poised to replace routine mediastinoscopy within the next five years.

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd.
Unit Number: 1489
Houston, TX 77030
Room Number: FCT19.6000
Phone: (713) 794-1477
Fax: (713) 794-4901
Email: drice@mdanderson.org

Education & Training

Degree-Granting Education

1991 The Medical School of Trinity College, The University of Dublin, Dublin, Ireland, MD, Medicine

Postgraduate Training

7/1999-6/2001 Resident, Cardiothoracic Surgery, Baylor College of Medicine and The University of Texas MD Anderson Cancer Center, Houston, TX, Dr. Michael Reardon
12/1998-4/1999 Fellow, Thoracic Surgery, Mayo Clinic, Rochester, MN, Dr. Peter Pairolerto
1/1996-6/1997 Postdoctoral Fellow, Mayo Clinic, Section of Colon and Rectal Surgery, Rochester, MN, Dr. Heidi Nelson
7/1992-12/1998 Residency, General Surgery, Mayo Clinic, Rochester, MN, Dr. David Farley
7/1991-6/1992 Intern, Surgical, St. James Hospital, Dublin, Ireland, Professor Thomas Hennesy
1987-6/1991 MB, Medicine, Medicine, Surgery, Art of Obstetrics, The Medical School of Trinity College, The University of Dublin, Dublin, Ireland, Professor, Donald G. Weir
1987-6/1991 BCh, Medicine, The Medical School of Trinity College, The University of Dublin, Dublin, Ireland, Professor, Donald G. Weir
1987-6/1991 BAO, Medicine, The Medical School of Trinity College, The University of Dublin, Dublin, Ireland, Professor, Donald G. Weir

Board Certifications

6/2004 The American Board of Thoracic Surgery
2/2002 The American Board of Surgery
7/1997 Fellow, The Royal College of Surgeons Ireland
1993 FLEX
8/1992 Education Commission for Foreign Medical Graduates

Experience/Service

Academic Appointments

Associate Professor, Department of Thoracic and Cardiovascular Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2006-8/2012
Assistant Professor, Department of Thoracic and Cardiovascular Surgery, Division of Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 8/2001-8/2006

Administrative Appointments/Responsibilities

Program Director (authorized GSBS program), The University of Texas MD Anderson Cancer Center, Houston, TX, 1/2004-present
Co-director, The University of Texas MD Anderson Cancer Center, Houston, TX, 1/2004-present
Program Director (authorized GSBS program), The University of Texas MD Anderson Cancer Center, Houston, 1/2003-2008

Consultantships

Consultant Surgeon, St. Luke's Episcopal Hospital, Houston, TX, 5/2011-present

Honors and Awards

2006 The Surgery Chief Resident Teaching Award, The University of Texas-Houston Medical School Department of Surgery
2004 Award on Aging, Society of Thoracic Surgeons
2002 The Surgery Chief Resident Teaching Award, The University of Texas-Houston Medical School Department of Surgery
1997 Kaare K. Nygaard Travel Award for Clinical Research
1995 Travel Prize, America Society of Colon and Rectal Surgeons
1991 Arthur Ball Memorial Prize in Surgery, Trinity College Dublin, Ireland
1991 Graduated with Class II Honors, Trinity College, Dublin, Ireland

Professional Memberships

American Association for Thoracic Surgery, Beverly, MA
Member, 5/2009-present
American College of Chest Physicians
Member, 8/2003-present
American College of Surgeons Oncology Group (ACOSOG), Durham, NC
Member, 9/2002-present
American Medical Association
Member, 6/1992-present
General Thoracic Surgical Club, Zumbrota, MN
Member, 3/2005-present
IASLC Mesothelioma Staging Committee, London, United Kingdom
Member, 2/2009-present
Michael E. DeBakey International Surgical Society
Member, 7/1999-present
Southern Thoracic Surgical Association, Chicago, IL
Member, 11/2004-present
SWOG, Ann Arbor, MI
Member, 3/2013-present
The Society of Laparoendoscopic Surgeons
Member, 1/2003-present
The Society of Thoracic Surgeons, Chicago, IL
Active Member, 1/2005-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Gold KA, Kim ES, Liu DD, Yuan P, Behrens C, Solis LM, Kadara H, Rice DC, Wistuba II, Swisher SG, Hofstetter WL, Lee JJ, Hong WK. Prediction of survival in resected non-small cell lung cancer using a protein-expression based risk model: Implications for personalized chemoprevention and therapy. Clin Cancer Res 20(7):1946-54, 4/1/2014. e-Pub 12/23/2013. PMID: 24366692.
2. Sudo K, Taketa T, Correa AM, Campagna MC, Wadhwa R, Blum MA, Komaki R, Lee JH, Bhutani MS, Weston B, Skinner HD, Maru DM, Rice DC, Swisher SG, Hofstetter WL, Ajani JA. Locoregional Failure Rate After Preoperative Chemoradiation of Esophageal Adenocarcinoma and the Outcomes of Salvage Strategies. J Clin Oncol 31(34):4306-10, 12/1/2013. e-Pub 10/21/2013. PMCID: PMC3837091.
3. Suzuki A, Xiao L, Taketa T, Sudo K, Wadhwa R, Blum MA, Skinner H, Komaki R, Weston B, Lee JH, Bhutani MS, Rice DC, Maru DM, Erasmus J, Swisher SG, Hofstetter WL, Ajani JA. Results of the baseline positron emission tomography can customize therapy of localized esophageal adenocarcinoma patients who achieve a clinical complete response after chemoradiation. Ann Oncol 24(11):2854-9, 11/2013. e-Pub 8/29/2013. PMID: 23994746.
4. Cheedella NK, Suzuki A, Xiao L, Hofstetter WL, Maru DM, Taketa T, Sudo K, Blum MA, Lin SH, Welch J, Lee JH, Bhutani MS, Rice DC, Vaporciyan AA, Swisher SG, Ajani JA. Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort. Ann Oncol 24(5):1262-6, 5/2013. e-Pub 12/17/2012. PMCID: PMC3629896.
5. Lopez Guerra JL, Gomez DR, Lin SH, Levy LB, Zhuang Y, Komaki R, Jaen J, Vaporciyan AA, Swisher SG, Cox JD, Liao Z, Rice DC. Risk factors for local and regional recurrence in patients with resected N0-N1 non-small-cell lung cancer, with implications for patient selection for adjuvant radiation therapy. Ann Oncol 24(1):67-74, 1/2013. e-Pub 9/20/2012. PMCID: PMC3525136.
6. Ajani JA, Correa AM, Hofstetter WL, Rice DC, Blum MA, Suzuki A, Taketa T, Welsh J, Lin SH, Lee JH, Bhutani MS, Ross WA, Maru DM, Macapinlac HA, Erasmus J, Komaki R, Mehran RJ, Vaporciyan AA, Swisher SG. Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer. Ann Oncol 23(10):2638-42, 10/2012. e-Pub 7/24/2012. PMCID: PMC3457750.
7. Gomez DR, Cox JD, Roth JA, Allen PK, Wei X, Mehran RJ, Kim JY, Swisher SG, Rice DC, Komaki R. A prospective phase 2 study of surgery followed by chemotherapy and radiation for superior sulcus tumors. Cancer. e-Pub 6/28/2011. PMID: 21713767.
8. Stephens EH, Blackmon SH, Correa AM, Roth JA, Rice DC, Hofstetter W, Benjamin R, Mehran R, Swisher SG, Walsh GL, Vaporciyan AA. Progression after Chemotherapy Is a Novel Predictor of Poor Outcomes after Pulmonary Metastasectomy in Sarcoma Patients. J Am Coll Surg 212(5):821-6, 5/2011. e-Pub 3/23/2011. PMID: 21435923.
9. Tang X, Kadara H, Behrens C, Liu DD, Xiao Y, Rice D, Gazdar AF, Fujimoto J, Moran C, Varella-Garcia M, Lee JJ, Hong WK, Wistuba II. Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: Implications in lung cancer pathogenesis and prognosis. Clin Cancer Res 17(8):2434-43, 4/15/2011. e-Pub 1/21/2011. PMCID: PMC3078948.
10. Mehran R, Rice D, El-Zein R, Huang JL, Vaporciyan A, Goodyear A, Mehta A, Correa A, Walsh G, Roth J, Swisher S, Hofstetter W. Minimally invasive esophagectomy versus open esophagectomy, a symptom assessment study. Dis Esophagus 24(3):147-52, 4/2011. e-Pub 10/11/2010. PMID: 21040152.
11. Kountourakis P, Correa AM, Hofstetter WL, Lee JH, Bhutani MS, Rice DC, Komaki R, Maru DM, Ross WA, Vaporciyan A, Swisher SG, Ajani JA. Combined modality therapy of cT2N0M0 esophageal cancer: the University of Texas M. D. Anderson Cancer Center experience. Cancer 117(5):925-30, 3/1/2011. e-Pub 10/19/2010. PMCID: PMC3080168.
12. Gaur P, Sepesi B, Hofstetter WL, Correa AM, Bhutani MS, Watson TJ, Swisher SG, M. D. Anderson Esophageal Cancer Group, University of Rochester School of Medicine and Dentistry Foregut Group. Endoscopic esophageal tumor length: a prognostic factor for patients with esophageal cancer. Cancer 117(1):63-9, 1/2011. e-Pub 8/2010. PMID: 20803613.
13. Hayashi Y, Correa AM, Hofstetter WL, Vaporciyan AA, Rice DC, Walsh GL, Mehran RJ, Lee JH, Bhutani MS, Dekovich A, Swisher SG, Ajani JA. The influence of high body mass index on the prognosis of patients with esophageal cancer after surgery as primary therapy. Cancer 116(24):5619-5627, 12/15/2010. e-Pub 11/8/2010. PMID: 21136578.
14. Ajani JA, Correa AM, Walsh GL, Komaki R, Lee JH, Vaporciyan AA, Rice DC, Yao JC, Maru DM, Hofstetter WL, Phan AT, Swisher SG. Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction. Cancer 116(7):1656-63, 4/2010. e-Pub 2/2010. PMID: 20143431.
15. Rice DC, Stevens CW, Correa AM, Vaporciyan AA, Tsao A, Forster KM, Walsh GL, Swisher SG, Hofstetter WL, Mehran RJ, Roth JA, Liao Z, Smythe WR. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg 84(5):1685-1692, Jul-Aug, 11/2007. PMID: 17954086.
16. Rice DC, Smythe WR, Liao Z, Guerrero T, Chang JY, McAleer MF, Jeter MD, Correa A, Vaporciyan AA, Liu HH, Komaki R, Forster KM, Stevens CW. Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 69(2):350-7, Jul-Aug, 10/1/2007. PMID: 17467922.
17. Rohatgi P, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, Walsh GL, Vaporciyan AA, Rice DC, Roth JA, Ajani JA. Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer 104(11):2365-72, Nov-Dec, 12/2005. PMID: 16245310.
18. Rohatgi PR, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, Walsh G, Vaporciyan A, Lynch PM, Rice DC, Roth JA, Ajani JA. Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus. Cancer 104(7):1349-55, Nov-Dec, 10/2005. PMID: 16130133.
19. Swisher SG, Hofstetter W, Wu TT, Correa AM, Ajani JA, Komaki RR, Chirieac L, Hunt KK, Liao Z, Phan A, Rice DC, Vaporciyan AA, Walsh GL, Roth JA. Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). Ann Surg 241(5):810-7; discussion 817-20, Nov-Dec, 5/2005. PMID: 15849517.
20. Swisher SG, Erasmus J, Maish M, Correa AM, Macapinlac H, Ajani JA, Cox JD, Komaki RR, Hong D, Lee HK, Putnam JB, Rice DC, Smythe WR, Thai L, Vaporciyan AA, Walsh GL, Wu TT, Roth JA. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 101(8):1776-85, Nov-Dec, 10/2004. PMID: 15386332.
21. Swisher SG, Maish M, Erasmus JJ, Correa AM, Ajani JA, Bresalier R, Komaki R, Macapinlac H, Munden RF, Putnam JB, Rice D, Smythe WR, Vaporciyan AA, Walsh GL, Wu TT, Roth JA. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg 78(4):1152-1160, Nov-Dec, 2004. PMID: 15464463.
22. Ahamad A, Stevens CW, Smythe WR, Liao Z, Vaporciyan AA, Rice D, Walsh G, Guerrero T, Chang J, Bell B, Komaki R, Forster KM. Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMRT) to the chest. Cancer J 9(6):476-484, Nov-Dec, 2003. PMID: 14740977.
23. Hofstetter W, Swisher SG, Correa AM, Hess K, Putnam JB, Jr, Ajani JA, Dolormente M, Francisco R, Komaki RR, Lara A, Martin F, Rice DC, Sarabia AJ, Smythe WR, Vaporciyan AA, Walsh GL, Roth JA. Treatment outcomes of resected esophageal cancer. Ann Surg 236(3):376-84; discussion 384-5, 9/2002. PMID: 12192324.

Invited Articles

1. Rice DC, Yu P. Use of supercharged jejunal flap for esophageal reconstruction. Operative Techniques in Thoracic and Cardiovascular Surgery 15(3):243-257, 9/2010.
2. Rice DC, Reardon MJ. Left heart sarcomas. Methodist Debakey Cardiovasc J 6(3):49-56, Jul-Sep, 7/2010. PMID: 20834212.
3. Rice DC. Further considerations in the treatment of locally advanced lung cancer. Oncology (Williston Park) 24(3):241, 247, 253, 3/2010. PMID: 20394136.
4. Bakaeen FG, Jaroszewski DE, Rice DC, Walsh GL, Vaporciyan AA, Swisher SS, Benjamin R, Blackmon S, Reardon MJ. Outcomes after surgical resection of cardiac sarcoma in the multimodality treatment era. J Thorac Cardiovasc Surg 137(6):1454-60, 6/2009. e-Pub 4/2009. PMID: 19464464.
5. Rice, DC. Surgery for malignant pleural mesothelioma. Ann Diagn Pathol 13(1):65-72, Feb, 2/2009.
6. Nigam R, de Villalobos D, Rice D, Rozner MA, Nates JL. Acute postoperative superior vena cava syndrome. J Cardiothorac Vasc Anesth 22(4):584-6, Jul-Aug, 8/2008. PMID: 18662637.
7. Kent M, Rice D, Flores R. Diagnosis, Staging and Surgical Treatment of Malignant Pleural Mesothelioma. Curr Treat Options Oncol 9(2-3):158-170, 6/2008. e-Pub 8/2008. PMID: 18758965.
Other Articles
1. Rice D. Invited commentary. Ann Thorac Surg 89(1):210-1, 1/2010. PMID: 20103237.

Book Chapters

1. Rice DC. The Staging of Lung Cancer. In: Diagnostic Pathology of Pleuropulmonary Neoplasia. Ed(s) Weissferdt A, Moran CA. Springer: New York, 39-51, ISBN 978-1-4419-0787-5, e-Book 2013. ISBN: 978-1-4419-0786-8.
2. Rice D. Malignant Pleural and Pericardial Effusions in Breast Cancer. In: Advanced Therapy of Breast Disease, 3rd. Ed(s) GV Babiera, RJ Skoracki, FJ Esteva. People's Medical Publishing House-USA: Shelton, Connecticut, 1035-1047, 2012. ISBN: 978-1-60795-094-3.
3. Rice D. Surgical Therapy of Mesothelioma. In: Recent Results Cancer Res. 189, 97-125, 2011. ISBN: 21479898.
4. Suster S, Moran CA, Rice DC. Mediastinum. In: Intraoperative Consultation in Surgical Pathology. Ed(s) Ranchod M. Cambridge University Press: United Kingdom, 77-91, 2010. ISBN: 978-0-521-89767-9.

Manuals, Teaching Aids, Other Teaching Publications

1. Rice DC. Diagnosis and management of lung cancer: ACCP evidence-based clinical practice guidelines (3rd Edition), 2010.

Last updated: 7/23/2014